Kinase inhibitor therapy in CML: it's what's inside that counts.
Howard Hughes Medical Institute; Division of Hematology and Medical Oncology, Oregon Health and Science University, Knight Cancer Institute, Portland, OR.
Christopher A
CA
Eide
Brian J
BJ
Druker
Thomas
T
O'Hare
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate